Apiosporamide, A 4-hydroxy-2-pyridone Alkaloid, Induces Apoptosis Via PI3K/Akt Signaling Pathway In Osteosarcoma Cells

References

• Luetke A, Meyers PA, Lewis A, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532. doi:10.1016/j.ctrv.2013.11.00624345772
   PubMed Web of Science ®Google Scholar
• Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65–92.25070231
   PubMedGoogle Scholar
• Wycislo KL, Fan TM. The immunotherapy of canine osteosarcoma: a historical and systematic review. J Vet Intern Med. 2015;29(3):759–769. doi:10.1111/jvim.1254225929293
   PubMed Web of Science ®Google Scholar
• Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2009;152:239–262.20213394
   PubMedGoogle Scholar
• Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther. 2018;18(1):39–50. doi:10.1080/14737140.2018.141393929210294
   PubMed Web of Science ®Google Scholar
• Meyers PA. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther. 2009;9(8):1035–1049. doi:10.1586/era.09.6919671023
   PubMed Web of Science ®Google Scholar
• He JP, Hao Y, Wang XL, et al. Review of themolecular pathogenesis of osteosarcoma. Asian Pac J Cancer Prev. 2014;15(15):5967–5976. doi:10.7314/APJCP.2014.15.15.596725124559
   PubMedGoogle Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2012;29(2):144–222. doi:10.1039/c2np00090c22193773
   PubMed Web of Science ®Google Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2013;30:237–323.23263727
   PubMed Web of Science ®Google Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2014;31(2):160–258. doi:10.1039/c3np70117d24389707
   PubMed Web of Science ®Google Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2015;32(2):116–121. doi:10.1039/c4np00144c25620233
   PubMed Web of Science ®Google Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR. Marine natural products. Nat Prod Rep. 2016;33(3):382–431. doi:10.1039/c5np00156k26837534
   PubMed Web of Science ®Google Scholar
• Blunt JW, Copp BR, Keyzers RA, Munro MHG, Prinsep MR. Marine natural products. Nat Prod Rep. 2017;34(3):235–294. doi:10.1039/c6np00124f28290569
   PubMed Web of Science ®Google Scholar
• Mioso R, Marante FJ, Bezerra RS, Borges FV, Santos BV, Laguna IH. Cytotoxic compounds derived from marine sponges: a review (2010–2012). Molecules. 2017;22(2):208. doi:10.3390/molecules22020208
   PubMed Web of Science ®Google Scholar
• Gammone MA, Riccioni G, Galvano F, D’Orazio N. Novel therapeutic strategies against cancer: marine-derived drugs may be the answer? Anticancer Agents Med Chem. 2016;16(12):1549–1557.26863883
   PubMed Web of Science ®Google Scholar
• Alfatafta AA, Gloer JB, Scott JA, Malloch D. Apiosporamide, a new antifungal agent from the coprophilous fungus Apiospora montagnei. J Nat Prod. 1994;57(12):1696–1702. doi:10.1021/np50114a0127714537
   PubMed Web of Science ®Google Scholar
• Williams DR, Kammler DC, Donnell AF, Goundry WR. Total synthesis of (+)-apiosporamide: assignment of relative and absolute configuration. Angew Chem Int Ed Engl. 2005;44(41):6715–6718. doi:10.1002/anie.20050201516187387
   PubMed Web of Science ®Google Scholar
• Bao J, Zhai H, Zhu K, et al. Bioactive pyridone alkaloids from a deep-sea-derived fungus Arthrinium sp. UJNMF0008. Mar Drugs. 2018;16(5):pii: E174. doi:10.3390/md16050174
   Web of Science ®Google Scholar
• Zhang YY, Zhang QQ, Song JL, Zhang L, Jiang CS, Zhang H. Design, synthesis, and antiproliferative evaluation of novel coumarin/2-cyanoacryloyl hybrids as apoptosis inducing agents by activation of caspase-dependent pathway. Molecules. 2018;23(8):pii: E1972. doi:10.3390/molecules23081972
   Web of Science ®Google Scholar
• Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142:164–175. doi:10.1016/j.pharmthera.2013.12.00424333502
   PubMed Web of Science ®Google Scholar
• Zhu M, Ying J, Lin C, et al. b-Escin inhibits the proliferation of osteosarcoma cells via blocking the PI3K/Akt pathway. RSC Adv. 2018;8:29637–29644. doi:10.1039/C8RA03578D
   PubMed Web of Science ®Google Scholar
• Shibazaki M, Taniguchi M, Yokoi T, et al. YM-215343, a novel antifungal compound from Phoma sp. QN04621. J Antibiot (Tokyo). 2004;57(6):379–382. doi:10.7164/antibiotics.57.37915323126
   PubMed Web of Science ®Google Scholar
• Shah MA, Schwartz GK. Cyclin-dependent kinases as targets for cancer therapy. Cancer Chemother Biol Response Modif. 2005;22:135–162.16110611
   PubMedGoogle Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–414. doi:10.1038/nrc265719440234
   PubMed Web of Science ®Google Scholar
• Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 2008;8:671–682. doi:10.1038/nrc239918650841
   PubMed Web of Science ®Google Scholar
• Volkmann N, Marassi FM, Newmeyer DD, Hanein D. The rheostat in the membrane: BCL-2 family proteins and apoptosis. Cell Death Differ. 2014;21:206–215. doi:10.1038/cdd.2014.11924162659
   PubMed Web of Science ®Google Scholar
• Xie X, Tang B, Zhou J, Gao Q, Zhang P. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine. Oncol Rep. 2013;30(2):773–782. doi:10.3892/or.2013.252023743572
   PubMed Web of Science ®Google Scholar
• Chang F, Lee JT, Navolanic PM, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17(3):590–603. doi:10.1038/sj.leu.240282412646949
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4:988–1004. doi:10.1038/nrd190216341064
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang ZR, Zhao N, Ma BA, Fan QY. VEGF silencing inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via PI3K/AKT signaling pathway. Cell Biochem Biophys. 2015;73(2):519–525. doi:10.1007/s12013-015-0692-727352347
   PubMed Web of Science ®Google Scholar
• Wang T, Gong X, Jiang R, Li H, Du W, Kuang G. Ferulic acid inhibits proliferation and promotes apoptosis via blockage of PI3K/Akt pathway in osteosarcoma cell. Am J Transl Res. 2016;8(2):968–980.27158383
   PubMed Web of Science ®Google Scholar
• Chen ZZ. Berberine induced apoptosis of human osteosarcoma cells by inhibiting phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signal pathway activation. Iran J Public Health. 2016;45(5):578–585.27398330
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase. Balpha Curr Biol. 1997;7(4):261–269. doi:10.1016/S0960-9822(06)00122-99094314
   PubMed Web of Science ®Google Scholar
• James SR, Downes CP, Gigg R, Grove SJ, Holmes AB, Alessi DR. Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation. Biochem J. 1996;315:709–713. doi:10.1042/bj31507098645147
   PubMed Web of Science ®Google Scholar
• Gagliardi PA, Puliafito A, Primo L. PDK1: at the crossroad of cancer signaling pathways. Semin Cancer Biol. 2018;48:27–35. doi:10.1016/j.semcancer.2017.04.01428473254
   PubMed Web of Science ®Google Scholar
• Wang G, Liu X, Xie J, Meng J, Ni X. PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the apoptosis of non-small cell lung cancer cells. Biosci Rep. 2019;39(5):pii: BSR20182099. doi:10.1042/BSR20182099
   Google Scholar
• Sussman M. “AKT”ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation. Trends Cardiovasc Med. 2007;17(7):235–240. doi:10.1016/j.tcm.2007.08.00317936205
   PubMed Web of Science ®Google Scholar
• Wu D, Tao J, Xu B, et al. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int. 2011;87:105–113. doi:10.1159/00032284921597260
   PubMed Web of Science ®Google Scholar
• Tsuruta F, Masuyama N, Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J Biol Chem. 2002;277(16):14040–14047. doi:10.1074/jbc.M10897520011842081
   PubMed Web of Science ®Google Scholar